Topic: mergers and acquisitions
Independent pharma and healthcare agency W2O Group bought 21GRAMS today in a deal that expands the parent group’s creative capabilities.
After months of regulatory scrutiny, the EU has given AbbVie and Allergan's $63 billion merger its first go-ahead in anticipation of an FTC decision.
Eli Lilly's $1.1 billion Dermira bid is smart, some analysts say, because it brings in both a marketed drug and a phase 3 atopic dermatitis asset.
With its Upjohn spinoff in the works, Pfizer could look a mess after the deal closes. But in the long run, the future is bright, one analyst said.
Clovis' stock is down on a disappointing performance from its sole product, the PARP inhibitor Rubraca. That could make Clovis a target of M&A talk.
AbbVie has an answer to worries Allergan's aesthetics business will drag on its bottom line: Just keep the business separate.
Allergan's best-selling Botox and other promising meds may not be enough to fill the Humira gap. What could help? Hiving off assets, one analyst says.
What does it take to win a buyout bidding war? In Sanofi's $2.5 billion pick up of Synthorx, a little luck and a lot of money helped win the day.
On the heels of Novartis' $9.7 billion pick-up of MedCo, Amarin is now back at the center of the rumor mill among pharma M&A speculators.
Investors are clamoring for a CVR created in the BMS-Celgene deal, but it will only pay off if the FDA approves three hot pipeline projects.